[期刊论文][Short communication]

出版年：2018

α₁-Adrenoceptor (α₁-AR) antagonists are considered to be the most effective monotherapy agents for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). In this study, we synthesized compounds 2-17, which are novel piperazine derivatives that contain methyl phenylacetate. We then evaluated the vasodilatory activities of these compounds. Among them, we found that compounds 2, 7, 12, which contain 2-OCH₃, 2-CH₃or 2, 5-CH₃, respectively, exhibited potent α₁-blocking activity similar to protype drug naftopidil (1). The antagonistic effects of 2, 7, and 12 on the (-)-noradrenaline-induced contractile response of isolated rat prostatic vas deferens (α_1A), spleen (α_1B) and thoracic aorta (α_1D) were further characterized to assess the sub receptor selectivity. Compared with naftopidil (1) and terazosin, compound 12 showed the most desirable α_1D/1Asubtype selectivity, especially improved α_1Asubtype selectivity, and the ratios pA₂(α_1D)/pA₂(α_1B) and pA₂(α_1A)/pA₂(α_1B) were 17.0- and 19.5-fold, respectively, indicating less cardiovascular side effects when used to treat LUTS/BPH. Finally, we investigated the chiral pharmacology of 12. We found, however, that the activity of enantiomers (R)-12 and (S)-12 are not significantly different from that of rac-12. Copyright © 2018 Elsevier Ltd. All rights reserved.

α ₁-Adrenoreceptor ; Benign prostatic hyperplasia ; Piperazine derivatives ; Functional assays